Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1437-7772
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases ; day:6 ; month:5 ; year:2017 ; pages:1-10
International journal of clinical oncology ; (6.5.2017), 1-10
- Keyword
-
Krebs
Onkologie
- Creator
-
Uemura, Hiroji
- Contributor
-
Uemura, Hirotsugu
Matsubara, Nobuaki
Kinuya, Seigo
Hosono, Makoto
Yajima, Yoko
Doi, Toshihiko
SpringerLink (Online service)
- DOI
-
10.1007/s10147-017-1130-1
- URN
-
urn:nbn:de:1111-201705192466
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Uemura, Hiroji
- Uemura, Hirotsugu
- Matsubara, Nobuaki
- Kinuya, Seigo
- Hosono, Makoto
- Yajima, Yoko
- Doi, Toshihiko
- SpringerLink (Online service)
Other Objects (12)
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223
Pharmacokinetics of single dose radium-223 dichloride (BAY 88-8223) in Japanese patients with castration-resistant prostate cancer and bone metastases
Phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
The value of baseline 18F-sodium fluoride and 18F-choline PET activity for identifying responders to radium-223 treatment in castration-resistant prostate cancer bone metastases
Targeting molecular resistance in castration-resistant prostate cancer
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer
Osteoclasts directly influence castration-resistant prostate cancer cells
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223